Connect Biopharma Enhances its Intellectual Property Estate for CBP307 a Targeted Therapy with Potential in Multiple Autoimmune Diseases with Patent Issuances in the United States EU Japan and Australia

Novel nextgeneration S1P1 agonist currently in Phase 2 clinical development for treatment of inflammatory bowel disease SAN DIEGO and TAICANG China Feb. 25 2020 PRNewswire Connect Biopharma a clinicalstage biopharmaceutical company focused on identifying ...